Autopsy report · NCT03369964

A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

“Business decision: no safety or efficacy concerns.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Hoffmann-La Roche

Sponsor type

Industry

Conditions

Lymphoma, Non-Hodgkin

Interventions

Atezolizumab; Emactuzumab; Obinutuzumab

Participants

0

Sites

2

Countries

United States

Trials that died the same way

• Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes
  “Business Decision; No Safety Or Efficacy Concerns. (See below)” (92% match in meaning)
• A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
  “Business decision, insufficient enrollment, no safety or efficacy concerns.” (81% match in meaning)
• A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
  “This was a strategic business decision. There were no safety concerns contributing to this decision.” (77% match in meaning)
• Study of Poziotinib in Japanese Patients With NSCLC
  “Business decision, not related to safety.” (76% match in meaning)
• Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
  “Company decision not related to any safety concerns.” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.